MCID: SLV012
MIFTS: 52

Salivary Gland Adenoid Cystic Carcinoma malady

Categories: Rare diseases, Cancer diseases, Oral diseases, Skin diseases, Endocrine diseases

Aliases & Classifications for Salivary Gland Adenoid Cystic Carcinoma

About this section

Aliases & Descriptions for Salivary Gland Adenoid Cystic Carcinoma:

Name: Salivary Gland Adenoid Cystic Carcinoma 11 13 48
Adenoid Cystic Carcinoma 11 46 66
Cylindroma 11 46
Adenoid Cystic Carcinoma of Salivary Gland 66
Eccrine Dermal Cylindroma 66
Carcinoma, Adenoid Cystic 37
 
Carcinoma Adenoid Cystic 48
Adenoid Cystic Cancer 11
Adenocystic Carcinoma 46
Carcinoma, Cribriform 66
Cribriform Carcinoma 46
Cylindroma Nos 11

Classifications:



External Ids:

Disease Ontology11 DOID:4866
MeSH37 D003528
NCIt43 C2970

Summaries for Salivary Gland Adenoid Cystic Carcinoma

About this section
NIH Rare Diseases:46 Adenoid cystic carcinoma (acc) is a rare form of adenocarcinoma, which is cancer that begins in gladular tissues. acc most commonly arises in the head and neck, in various parts of the major and minor salivary glands including the palate, nasopharynx, lining of the mouth, voice box (larynx) or windpipe (trachea). it can also occur in the breast, uterus, or other locations in the body. early symptoms depend on the tumor's location and may include lumps under the lining of the mouth or facial skin; numbness in the mouth or face; difficulty swallowing; hoarseness; pain; or paralysis of a facial nerve. acc often has long periods with no growth followed by growth spurts; however, it can be aggressive in some people. acc spreads along nerves or through the bloodstream, and only spreads to the lymph nodes in about 5-10% of cases. the cause of acc is currently unknown. treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. last updated: 12/10/2014

MalaCards based summary: Salivary Gland Adenoid Cystic Carcinoma, also known as adenoid cystic carcinoma, is related to cribriform carcinoma and bartholin's gland adenoid cystic carcinoma, and has symptoms including pain and pain. An important gene associated with Salivary Gland Adenoid Cystic Carcinoma is RUNX3 (Runt Related Transcription Factor 3), and among its related pathways are Syndecan-3-mediated signaling events and Immune response_Oncostatin M signaling via JAK-Stat in human cells. Affiliated tissues include salivary gland, skin and breast, and related mouse phenotypes are no phenotypic analysis and embryo.

Disease Ontology:11 A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. these structures are typically filled with a mucous-like material or contain abnormal fibrous membranes.

Related Diseases for Salivary Gland Adenoid Cystic Carcinoma

About this section

Diseases related to Salivary Gland Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 113)
idRelated DiseaseScoreTop Affiliating Genes
1cribriform carcinoma33.3EGFR, KIT
2bartholin's gland adenoid cystic carcinoma32.8EGFR, KIT, PGR
3prostate adenoid cystic carcinoma27.7AQP1, CCND1, CTTN, CYLD, EGFR, EN1
4cervical adenoid cystic carcinoma12.4
5maxillary sinus adenoid cystic carcinoma12.4
6lacrimal gland adenoid cystic carcinoma12.4
7esophageal adenoid cystic carcinoma12.4
8laryngeal adenoid cystic carcinoma12.3
9breast adenoid cystic carcinoma12.3
10lung adenoid cystic carcinoma12.2
11trachea adenoid cystic carcinoma12.2
12ethmoid sinus adenoid cystic carcinoma12.2
13parotid gland adenoid cystic carcinoma12.2
14adenoid cystic carcinoma of the corpus uteri12.2
15malignant cylindroma12.1
16cutaneous adenocystic carcinoma12.1
17adnexal spiradenoma/cylindroma of a sweat gland11.9
18poncet-spiegler's cylindroma11.9
19brooke-spiegler syndrome11.7
20cylindromatosis, familial11.6
21lymph node adenoid cystic carcinoma11.1
22adenoiditis11.0
23emphysematous cholecystitis10.7NOS2, VEGFA
24peripheral nervous system disease10.5KIT, NOS2
25scn8a encephalopathy10.4NOS2, VEGFA
26spiradenoma10.4
27ocular melanoma10.4KIT, VEGFA
28facial nerve disease10.3KIT, VEGFA
29perivascular epithelioid cell tumor10.3KIT, VEGFA
30pancreatic serous cystic neoplasm10.3PGR, VEGFA
31gallbladder angiosarcoma10.3KIT, PGR
32vaginal adenosarcoma10.2KIT, PGR
33adenosine monophosphate deaminase 1 deficiency10.2PGR, VEGFA
34lens disease10.2AQP1, VEGFA
35endotheliitis10.2
36dysembryoplastic neuroepithelial tumor10.2KIT, PGR
37infiltrative basal cell carcinoma10.2KIT, PGR
38focal chorioretinitis10.2KIT, PGR
39rheumatic pulmonary valve disease10.2PGR, VEGFA
40cholesteatoma of external ear10.2KIT, PGR
41parachordoma10.2KIT, PGR
42gastric fundus cancer10.2CCND1, RUNX3, VEGFA
43gastric small cell carcinoma10.2PGR, VEGFA
44nasopharynx carcinoma10.2CCND1, KIT
45clear cell hidradenoma10.2KIT, PGR
46lethal restrictive dermopathy, lmna-related10.1EGFR, VEGFA
47gallbladder squamous cell carcinoma10.1CCND1, PGR
48amyloid tumor10.1CCND1, PGR
49mucinous cystadenocarcinoma10.1EGFR, VEGFA
50vibratory urticaria10.1KIT, PGR

Graphical network of the top 20 diseases related to Salivary Gland Adenoid Cystic Carcinoma:



Diseases related to salivary gland adenoid cystic carcinoma

Symptoms for Salivary Gland Adenoid Cystic Carcinoma

About this section

UMLS symptoms related to Salivary Gland Adenoid Cystic Carcinoma:


pain

Drugs & Therapeutics for Salivary Gland Adenoid Cystic Carcinoma

About this section

Drugs for Salivary Gland Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 76)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DocetaxelApproved May 1996Phase 3, Phase 1, Phase 21880114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
2
MiconazolePhase 2, Phase 3, Phase 1357322916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
3
MegestrolPhase 3643562-63-819090, 3080587
Synonyms:
(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
3562-63-8
AC1L2DG3
C07120
CID19090
Chronopil
Chronopil (TN)
D008535
D08167
DB00351
 
EINECS 222-628-6
HSDB 3233
LS-118488
MGA
Megestrol (INN)
Megestrol Acetate
Megestrol [INN:BAN]
Megestrolo
Megestrolo [DCIT]
Megestrolum [INN-Latin]
Megestryl acetate
UNII-EA6LD1M70M
megestrol
4
Megestrol acetatePhase 364595-33-511683
Synonyms:
17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
17alpha-Acetoxy-6-dehydro-6-methylprogesterone
17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
17α-Acetoxy-6-dehydro-6-methylprogesterone
17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
6-Dehydro-6-methyl-17alpha-acetoxyprogesterone
6-Dehydro-6-methyl-17α-acetoxyprogesterone
6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione
 
6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-17α-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17α-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-6-dehydro-17alpha-acetoxyprogesterone
6-Methyl-6-dehydro-17α-acetoxyprogesterone
6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate
6-Methyl-delta(sup 4,6)-pregnadien-17α-ol-3,20-dione acetate
6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone
6-Methyl-delta(sup 6)-dehydro-17α-acetoxyprogesterone
MGA
Megace
5
FluconazolePhase 2, Phase 317386386-73-43365
Synonyms:
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
86386-73-4
AC-428
AC1L1FRQ
AC1Q77FV
AKOS000280854
AbZ Brand of Fluconazole
Afungil
Alflucoz
Aliud Brand of Fluconazole
Alpharma Brand of Fluconazole
Apo Fluconazole
Apo-Fluconazole
Apotex Brand of Fluconazole
Armstrong Brand of Fluconazole
BIDD:GT0799
BRD-K05977355-001-02-6
BSPBio_003504
Baten
Beagyne
Bio-0041
Biocanol
Biozole
Biozolene
C13H12F2N6O
CCRIS 7211
CHEBI:46081
CHEMBL106
CID3365
CPD000471882
Canzol
Chemia Brand of Fluconazole
Cryptal
D00322
D015725
DB00196
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
DIFLUCAN IN SODIUM CHLORIDE 0.9%
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
DRG-0005
Diflazon
Diflucan
Diflucan (TN)
Diflucan, Trican, Alfumet, Fluconazole
Dimycon
DivK1c_001030
Effik Brand of Fluconazole
Elazor
F0677
F8929_SIGMA
FCZ
FLCZ
Fluc Hexal
Flucazol
FlucoLich
Flucobeta
Fluconazol
Fluconazol AL
Fluconazol AbZ
Fluconazol Isis
Fluconazol Stada
Fluconazol [Spanish]
Fluconazol ratiopharm
Fluconazol von ct
Fluconazol-Isis
Fluconazol-ratiopharm
Fluconazole & Bovine Lactoferrin
Fluconazole & Human recombinant granulocyte colony stimulating factor
Fluconazole & MC-510,011
Fluconazole & hGCSF
Fluconazole (JAN/USAN/INN)
Fluconazole [USAN:INN:BAN:JAN]
Fluconazole in combination with MGCD290
Fluconazole in dextrose 5% in plastic container
Fluconazole in sodium chloride 0.9%
Fluconazole in sodium chloride 0.9% in plastic container
Fluconazolum
Fluconazolum [Latin]
Flucostat
 
Flucytosine & Nyotran
Flucytosine & Nyotran(Liposomal Nystatin)
Flukezol
Flunazul
Flunizol
Fluzone
Forcan
Fuconal
Fungata
GL663142 & Fluconazole
HMS1922O10
HMS2090I20
HMS2093M21
HMS503M21
HSDB 7420
Hexal Brand of Fluconazole
I06-0069
IDI1_001030
KBio1_001030
KBio2_002134
KBio2_004702
KBio2_007270
KBio3_003009
KBioGR_000360
KBioSS_002134
KS-1059
LS-1858
Lavisa
Lesvi Brand of Fluconazole
Lichtenstein Brand of Fluconazole
Loitin
MLS001066394
MLS001165780
MLS001195645
MLS001304713
MLS001306492
Mack Brand of Fluconazole
MolPort-000-883-859
MolPort-002-885-825
Mutum
NCGC00095089-01
NCGC00095089-02
NCGC00095089-04
NCGC00095089-05
NINDS_001030
Neofomiral
Oxifugol
Oxifungol
Pfizer Brand of Fluconazole
Pfleger Brand of Fluconazole
Pritenzol
S1331_Selleck
SAM002589905
SAT Brand of Fluconazole
SMR000471882
SPBio_001613
SPECTRUM1503975
STK619301
Silanes Brand of Fluconazole
Solacap
Spectrum2_001607
Spectrum3_001912
Spectrum4_000090
Spectrum5_001277
Spectrum_001654
Stada Brand of Fluconazole
Syscan
TL8005609
TPF
Triflucan
UK 49858
UK-49858
UK49858
UNII-8VZV102JFY
Vita Brand of Fluconazole
XMP.284 & Fluconazole
XMP.366 & Fluconazole
XMP.391 & Fluconazole
ZINC00004009
Zemyc
Zoltec
Zonal
betapharm Brand of Fluconazole
ct Arzneimittel Brand of Fluconazole
ct-Arzneimittel Brand of Fluconazole
fluconazole
nchembio.100-comp3
nchembio.65-comp15
ratiopharm Brand of Fluconazole
6
CevimelinePhase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
7PorfiromycinPhase 34
8Alkylating AgentsPhase 3, Phase 2, Phase 14573
9
FentanylPhase 3739437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
10pancreatic polypeptidePhase 3, Phase 120
11
Histamine PhosphatePhase 3100851-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
12
DoxepinPhase 3131668-19-5667477, 667468
Synonyms:
(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(Z)-Doxepin
11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine
11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin
11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin
1668-19-5
3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
3607-18-9
AC1L1FAW
AC1LDI5F
AC1LDI63
AC1NUW4A
AKOS001582771
Adapin
Aponal
BPBio1_000118
BRD-K36616567-003-01-5
BRD-K37694030-003-02-8
BRD-K54462405-003-03-3
BSPBio_000106
BSPBio_001934
C06971
C19H21NO
CAS-1229-29-4
CCRIS 9176
CHEBI:36691
CHEBI:36692
CHEBI:4710
CHEMBL101740
CID10039438
CID3158
CID5462131
CID667468
CID667477
Cidoxepin
Cidoxepin [INN]
Cidoxepina
Cidoxepinum
Curatin
D07875
DB01142
DivK1c_000431
Doxepin
Doxepin (INN)
Doxepin (Z)-isomer
Doxepin Hcl
Doxepin Hydrochloride,
Doxepin [USAN]
 
Doxepin, Hydrochloride
Doxepina
Doxepina [INN-Spanish]
Doxepine
Doxepinum
Doxepinum [INN-Latin]
HSDB 3069
IDI1_000431
KBio1_000431
KBio2_001285
KBio2_003853
KBio2_006421
KBio3_001154
KBioGR_001131
KBioSS_001285
L000699
LS-174582
LS-61638
Lopac-D-4526
Lopac0_000339
MF 10
MOLI001594
MolPort-003-847-024
MolPort-005-933-834
N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine
NCGC00015344-01
NCGC00015344-02
NCGC00015344-04
NCGC00024623-01
NCGC00024623-02
NCGC00162127-01
NINDS_000431
Oprea1_473232
Prestwick0_000263
Prestwick1_000263
Prestwick2_000263
Prestwick3_000263
Quitaxon
SPBio_000206
SPBio_002325
Sinequan
Sinequan (TN)
Spectrum2_000133
Spectrum3_000407
Spectrum4_000526
Spectrum5_001051
Spectrum_000805
Tocris-0508
Triadapin
UNII-5ASJ6HUZ7D
UNII-F96TTB8728
Zonalon
cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin
cis-doxepin
doxepin
13
histaminePhase 3100975614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
14COLANutraceuticalPhase 3, Phase 1, Phase 21824
15
DoxilApproved June 1999Phase 2167631703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
16
LapatinibApproved March 2007Phase 2296231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
17
FluorouracilPhase 1, Phase 2172851-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
18
EniluracilPhase 1, Phase 21159989-18-3
Synonyms:
5-Ethynyluracil
 
5-ethynyl-2,4(1H,3H)-Pyrimidinedione
Compound 776C
19
EpirubicinPhase 1, Phase 237456420-45-241867
Synonyms:
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
4'-Epi-DXR
4'-Epiadriamycin
4'-Epidoxorubicin
4'-epi-DX
4'-epi-Doxorubicin
4'-epidoxorubicin
4-Epidoxorubicin
56390-09-1
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
AC1L26NP
AC1Q6JIV
BRN 1445813
C11230
C27H29NO11
CCRIS 2261
CHEBI:47898
CHEMBL417
CID41867
D07901
DB00445
Ellence
Epi-DX
Epi-Dx
Epiadriamycin
Epidoxorubicin
Epirubicin
 
Epirubicin (INN)
Epirubicin [INN:BAN]
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin (TN)
HSDB 6962
IMI 28
LS-187190
LS-93992
MLS000759412
NChemBio.2007.10-comp15
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SMR000466308
Triferric doxorubicin
UNII-3Z8479ZZ5X
WP 697
20
HydroxyureaPhase 1, Phase 2208127-07-13657
Synonyms:
1-HYDROXYUREA
127-07-1
4-03-00-00170 (Beilstein Handbook Reference)
55291_FLUKA
AC1L1GF8
AC1Q4ZXK
AI3-51139
BB_SC-7256
BRN 1741548
BSPBio_002164
Bio1_000451
Bio1_000940
Bio1_001429
Biosupressin
C07044
CCRIS 958
CHEBI:44423
CHEMBL467
CID3657
Carbamohydroxamic Acid
Carbamohydroxamic acid
Carbamohydroximic Acid
Carbamohydroximic acid
Carbamohydroxyamic Acid
Carbamohydroxyamic acid
Carbamoyl Oxime
Carbamoyl oxime
Carbamyl Hydroxamate
Carbamyl hydroxamate
Carrbamoyl Oxime
D00341
D006918
DB01005
DRG-0253
DivK1c_000556
Droxia
Droxia (TM)
Droxia (TN)
E0723DBA-5AF3-49D1-B5F6-59420AB87AC9
EINECS 204-821-7
EU-0100596
FT-0083575
H 8627
H0310
H20210
H8627_SIGMA
HMS1920F09
HMS2091L17
HMS501L18
HSDB 6887
HU
HYDREA (TN)
HYDROXY-UREA
Hidrix
Hidroxicarbamida
Hidroxicarbamida [INN-Spanish]
Hydrea
Hydrea (TM)
Hydrea, Biosupressin, Cytodrox, Hydroxyurea
Hydreia
Hydroxicarbamidum
Hydroxycarbamid
Hydroxycarbamide
Hydroxycarbamide (JAN/INN)
Hydroxycarbamidum
Hydroxycarbamidum [INN-Latin]
Hydroxycarbamine
Hydroxyharnstoff
Hydroxyharnstoff [German]
Hydroxylurea
Hydroxyurea
Hydroxyurea (D4)
Hydroxyurea (USP)
Hydroxyurea [USAN:BAN]
Hydroxyurea(d4)
 
Hydura
Hydurea
I05-0250
IDI1_000556
Idrossicarbamide
Idrossicarbamide [DCIT]
Idrossicarbamide [Dcit]
KBio1_000556
KBio2_001389
KBio2_003957
KBio2_006525
KBio3_001384
KBioGR_000383
KBioSS_001389
LS-709
Litaler
Litalir
Lopac-H-8627
Lopac0_000596
MLS001332381
MLS001332382
MLS002153389
MolMap_000029
MolPort-000-003-971
Mylocel
N-(Aminocarbonyl) Hydroxyamine
N-Carbamoylhydroxylamine
N-HYDROXY UREA
N-Hydroxymocovina
N-Hydroxymocovina [Czech]
N-Hydroxyurea
NCGC00015520-01
NCGC00015520-02
NCGC00015520-07
NCGC00093974-01
NCGC00093974-02
NCGC00093974-03
NCGC00093974-04
NCGC00093974-05
NCI C04831
NCI-C04831
NCI60_002773
NCIMech_000139
NHY
NINDS_000556
NSC 32065
NSC32065
Onco-Carbide
Onco-carbide
Oncocarbide
Oxyurea
S-phase/G-1 interface inhibitor
S1896_Selleck
SK 22591
SMR000059149
SPBio_000247
SPECTRUM1500344
SQ 1089
SQ-1089
Siklos
Spectrum2_000064
Spectrum3_000462
Spectrum4_000012
Spectrum5_000836
Spectrum_000909
Sterile Urea
TL8000673
UNII-X6Q56QN5QC
Ureaphil
WLN: ZVMQ
carbamide oxide
hydroxyaminomethanamide
hydroxyurea
nchembio.573-comp3
nchembio.90-comp4
nchembio749-comp3
tetratogen: inhibits ribonucleoside diphosphate reductase
21
AldesleukinPhase 239185898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
22
CarboplatinPhase 1, Phase 2194241575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
23
trastuzumabPhase 2, Phase 1751180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
24
VorinostatPhase 2, Phase 1240149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
25
OxaliplatinPhase 2136661825-94-35310940, 9887054, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
26
GefitinibPhase 2345184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
27
PaclitaxelPhase 2, Phase 1269133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
28lenograstimPhase 2, Phase 11178
29Imatinib MesylatePhase 2, Phase 1588123596
30
CisplatinPhase 2, Phase 1261415663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
31
DoxorubicinPhase 2167623214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
32razoxanePhase 239
33
SunitinibPhase 2493341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
34
BortezomibPhase 2783179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
35
CapecitabinePhase 2, Phase 11257154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
36
EverolimusPhase 2, Phase 11863159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
37
DexrazoxanePhase 23924584-09-671384
Synonyms:
(+)-(S)-4,4'-Propylenedi-2,6-piperazinedione
(+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane
(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane
(S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane
149003-01-0
2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)- (9CI)
24584-09-6
4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione
4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione hydrochloride
AC1L2G28
AC1OCF6D
AC1Q6LVI
ADR 529
BIDD:GT0068
BRN 5759131
C11H16N4O4
CHEBI:50223
CHEBI:50224
CHEMBL1200778
CHEMBL1738
CID6918223
CID71384
Cardioxane
D03730
D07807
DB00380
DB02444
Desrazoxane
Dexrazoxan
Dexrazoxane
Dexrazoxane (TN)
Dexrazoxane (USAN/INN)
Dexrazoxane HCl
Dexrazoxane [USAN:BAN:INN]
Dexrazoxane hydrochloride
 
Dexrazoxano
Dexrazoxano [INN-Spanish]
Dexrazoxanum
Dexrazoxanum [INN-Latin]
Dextrorazoxane
Dyzoxane
Eucardion
HSDB 7319
I06-1989
I14-10061
ICRF 187
ICRF 187 hydrochloride
ICRF-187
Icrf-187
LS-111911
NCI60_001367
NSC 169780
NSC169780
Razoxana [INN-Spanish]
Razoxane
Razoxane, (S)-Isomer
Razoxanum [INN-Latin]
Razoxin
S1222_Selleck
Savene
Soluble ICRF (L-isosomer)
Tepirone
TopoTect
Totect
Totect (TN)
Totect, ICRF-187, Zinecard, Cardioxane, Dexrazoxane Hydrochloride
Troxozone
UNII-048L81261F
UNII-5346058Q7S
Zinecard
Zinecard (TN)
dyzoxane
icrf-187
38
cetuximabPhase 1, Phase 2720205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
39
sirolimusPhase 2, Phase 1186353123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
40
BevacizumabPhase 2, Phase 11938216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
41
erlotinib hydrochloridePhase 1, Phase 2793183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
42
AxitinibPhase 2106319460-85-06450551
Synonyms:
319460-85-0
790713-39-2
AC-1539
AC1O51X3
AG 013736
AG-013736
AG-013736, Axitinib
AG-13736
AG013736
Axitinib
C503983
 
CID6450551
EC-000.2322
I14-1971
INLYTA
Inlyta
MolPort-006-392-413
N-methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide
N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamide
S1005_Selleck
ST51054130
UNII-C9LVQ0YUXG
ZINC03816287
axitinib
43
GemcitabinePhase 2, Phase 1192895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
44
RitonavirPhase 2856155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
45
protease inhibitorsPhase 25157
Synonyms:
 
protease inhibitors
46FluoridesPhase 1, Phase 2405
47
IndinavirPhase 2110150378-17-95362440
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-Pentonamide
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
150378-17-9
157810-81-6
157810-81-6 (sulfate (1:1) (salt))
166746-42-5
1c6y
1hsg
1hsh
1k6c
1sdt
1sdu
1sdv
1sgu
216884-06-9
2avo
2avs
2avv
2bpx
AC-20034
AC1L1U7I
AKOS000280989
BIDD:GT0378
BIDD:PXR0141
C07051
 
C36H47N5O4
CHEBI:44032
Compound J
Crixivan
Crixivan (TM)
DB00224
IDV
Indinavir (*1:1 Sulfate salt*)
Indinavir [USAN]
Indinavir anhydrous
Indinavir sulfate
Indinavir sulphate
Indinavir, Sulfate (1:1)
L 735524
L-735 524
L-735,524
L-735524
LS-173382
MK-639
MolPort-000-883-804
N-[2(R)-HYDROXY-1(S)-INDANYL]-5-[(2(S)-TERTIARY BUTYLAMINOCARBONYL)-4(3-PYRIDYLMETHYL)PIPERAZINO]-4(S)-HYDROXY-2(R)-PHENYLMETHYLPENTANAMIDE
NCGC00159460-02
NSC697197
Propolis & 4-Hydroxy-N-(2-hydroxy-2,3-dihydro-1H-1-indanyl)-N'-(1,1-dimethylethyl)-2-phenylmethyl-5-[4-(3-pyridylmethyl)-1-piperzinyl]hexanediamide
Propolis+Indinavir
RS-253
UNII-9MG78X43ZT
indinavir
48
lenvatinibPhase 249417716-92-8
Synonyms:
4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
 
E7080
Lenvatinib Mesylate
lenvatinib
49
EtoposidePhase 2121033419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
50
MechlorethaminePhase 236351-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
 
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine

Interventional clinical trials:

(show top 50)    (show all 105)
idNameStatusNCT IDPhase
1Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck CancerCompletedNCT00002507Phase 3
2Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
3Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck CancerCompletedNCT00090337Phase 3
4Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
5Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
6Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
7Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3
8Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyActive, not recruitingNCT01156142Phase 3
9Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant TumorsNot yet recruitingNCT02838602Phase 3
10Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By SurgeryWithdrawnNCT00041171Phase 3
11A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary GlandsCompletedNCT00886132Phase 2
12Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and NeckCompletedNCT00581360Phase 2
13A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary GlandsCompletedNCT01678105Phase 2
14Study of RAD001 in Adenoid Cystic CarcinomaCompletedNCT01152840Phase 2
15Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaCompletedNCT01558661Phase 2
16Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and NeckCompletedNCT00077428Phase 2
17Dovitinib in Adenoid Cystic CarcinomaCompletedNCT01417143Phase 2
18Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland CancersCompletedNCT00095563Phase 2
19Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and NeckCompletedNCT00017498Phase 2
20Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2
21Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1, Phase 2
22Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1, Phase 2
23Docetaxel in Treating Patients With Solid TumorsCompletedNCT00003565Phase 2
24Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck CancerCompletedNCT00448552Phase 2
25Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
26Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid TumorCompletedNCT00021047Phase 1, Phase 2
27Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth CancerCompletedNCT00004901Phase 1, Phase 2
28Imatinib Mesylate in Treating Patients With Salivary Gland CancerCompletedNCT00045669Phase 2
29Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
30Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung CancerCompletedNCT00021333Phase 2
31Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck CancerCompletedNCT00509665Phase 2
32Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland TumorCompletedNCT00079079Phase 2
33Iressa Study in Patients With Salivary Gland CancerCompletedNCT00509002Phase 2
34Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and NeckRecruitingNCT00180921Phase 2
35Adenoid Cystic Carcinoma, Erbitux, and Particle TherapyRecruitingNCT01192087Phase 1, Phase 2
36Testing Lenvatinib in Patients With Adenoid Cystic CarcinomaRecruitingNCT02780310Phase 2
37A Study of Apatinib in Metastatic Adenoid Cystic Carcinoma of the Head and NeckRecruitingNCT02775370Phase 2
38Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14RecruitingNCT02860936Phase 2
39Intensity-Modulated or Proton Radiation Therapy for Sinonasal MalignancyRecruitingNCT01586767Phase 2
4018F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyRecruitingNCT01806675Phase 1, Phase 2
41External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesRecruitingNCT00637637Phase 2
42Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14RecruitingNCT02857712Phase 2
43Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaActive, not recruitingNCT02098538Phase 2
44Study of Dovitinib (TKI258) in Adenoid Cystic CarcinomaActive, not recruitingNCT01524692Phase 2
45Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic CarcinomaActive, not recruitingNCT01175980Phase 2
46Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaActive, not recruitingNCT01604772Phase 2
47Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsActive, not recruitingNCT00859937Phase 2
48Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and NeckActive, not recruitingNCT01065844Phase 2
49Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable CancerActive, not recruitingNCT00003657Phase 2
50Antineoplaston Therapy in Treating Patients With Advanced Head and Neck CancerActive, not recruitingNCT00003489Phase 2

Search NIH Clinical Center for Salivary Gland Adenoid Cystic Carcinoma


Cochrane evidence based reviews: carcinoma, adenoid cystic

Genetic Tests for Salivary Gland Adenoid Cystic Carcinoma

About this section

Anatomical Context for Salivary Gland Adenoid Cystic Carcinoma

About this section

MalaCards organs/tissues related to Salivary Gland Adenoid Cystic Carcinoma:

34
Salivary gland, Skin, Breast, Lymph node, Uterus, Trachea, Brain

Animal Models for Salivary Gland Adenoid Cystic Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma:

39 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.3CTTN, EGFR, KIT, PGR, RUNX3, VEGFA
2MP:00053808.3CTTN, EGFR, EN1, KIT, PGR, VEGFA
3MP:00053828.0CCND1, EGFR, KIT, NOS2, RUNX3, VEGFA
4MP:00053697.6EGFR, EN1, KIT, NOS2, PGR, RUNX3
5MP:00053917.5AQP1, CCND1, EGFR, KIT, NOS2, VEGFA
6MP:00028737.5CCND1, CYLD, EGFR, EN1, KIT, PGR
7MP:00053817.3CCND1, CYLD, EGFR, KIT, NOS2, RUNX3
8MP:00053717.2CYLD, EGFR, EN1, KIT, PGR, RUNX3
9MP:00036317.1AQP1, CCND1, EGFR, EN1, KIT, NOS2
10MP:00053896.8AQP1, CCND1, CTTN, EGFR, EN1, KIT
11MP:00020066.8CCND1, CYLD, EGFR, KIT, NOS2, PGR
12MP:00107716.8CCND1, CYLD, EGFR, EN1, KIT, NOS2
13MP:00053906.7CCND1, EGFR, EN1, KIT, NOS2, PGR
14MP:00053886.7AQP1, CCND1, CTTN, CYLD, EGFR, KIT
15MP:00053856.6AQP1, CCND1, CTTN, EGFR, EN1, KIT
16MP:00053866.5AQP1, CCND1, CYLD, EN1, KIT, NOS2
17MP:00053876.4CCND1, CTTN, CYLD, EGFR, EN1, KIT
18MP:00053846.3CCND1, CTTN, CYLD, EGFR, EN1, KIT
19MP:00053786.1AQP1, CCND1, CTTN, CYLD, EGFR, EN1
20MP:00053796.1AQP1, CCND1, CYLD, EGFR, EN1, KIT
21MP:00053976.0AQP1, CCND1, CTTN, CYLD, EGFR, EN1
22MP:00053765.8AQP1, CCND1, CYLD, EGFR, EN1, KIT
23MP:00107685.5AQP1, CCND1, CTTN, CYLD, EGFR, EN1

Publications for Salivary Gland Adenoid Cystic Carcinoma

About this section

Articles related to Salivary Gland Adenoid Cystic Carcinoma:

(show top 50)    (show all 56)
idTitleAuthorsYear
1
Carcinoma-Associated Fibroblasts Lead the Invasion of Salivary Gland Adenoid Cystic Carcinoma Cells by Creating an Invasive Track. (26954362)
2016
2
Identification of methylated genes in salivary gland adenoid cystic carcinoma xenografts using global demethylation and methylation microarray screening. (27212063)
2016
3
Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. (26862087)
2016
4
Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but Not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. (27000157)
2016
5
Salivary gland adenoid cystic carcinoma. (26214665)
2015
6
Role of hypoxia-inducible factor-1I+ and CD146 in epidermal growth factor receptor-mediated angiogenesis in salivary gland adenoid cystic carcinoma. (25997612)
2015
7
Inhibition of STAT3 reduces proliferation and invasion in salivary gland adenoid cystic carcinoma. (26175943)
2015
8
MicroRNA-101-3p suppresses cell proliferation, invasion and enhances chemotherapeutic sensitivity in salivary gland adenoid cystic carcinoma by targeting Pim-1. (26693056)
2015
9
Aberrant Wnt-1/beta-catenin signaling and WIF-1 deficiency are important events which promote tumor cell invasion and metastasis in salivary gland adenoid cystic carcinoma. (26405993)
2015
10
Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. (25520866)
2014
11
Pim-1 acts as an oncogene in human salivary gland adenoid cystic carcinoma. (25551195)
2014
12
A study on the inhibition of VEGF expression in salivary gland adenoid cystic carcinoma cells via iNOS gene RNAi in vitro. (25065562)
2014
13
Aquaporin-1 promoter hypermethylation is associated with improved prognosis in salivary gland adenoid cystic carcinoma. (24493792)
2014
14
High expression of SOX2 is associated with poor prognosis in patients with salivary gland adenoid cystic carcinoma. (24828201)
2014
15
Differential expression of vascular endothelial growth factor in high- and low-metastasis cell lines of salivary gland adenoid cystic carcinoma. (24510998)
2014
16
19-year oncologic outcomes and the benefit of elective neck dissection in salivary gland adenoid cystic carcinoma. (24170702)
2013
17
Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. (22580922)
2012
18
Developmental transcription factor EN1--a novel biomarker in human salivary gland adenoid cystic carcinoma. (21800291)
2012
19
Salivary gland adenoid cystic carcinoma with cervical lymph node metastasis: a preliminary study of 62 cases. (22647764)
2012
20
High expression of the autophagy gene Beclin-1 is associated with favorable prognosis for salivary gland adenoid cystic carcinoma. (22712799)
2012
21
Critical regions and spreading of runt-related transcription factor-3 C-phosphate-G (CpG) island methylation in human salivary gland adenoid cystic carcinoma. (21658745)
2011
22
CpG island methylation profiling in human salivary gland adenoid cystic carcinoma. (21692051)
2011
23
Unfavorable clinical implications for hypermethylation of RUNX3 in patients with salivary gland adenoid cystic carcinoma. (21567090)
2011
24
Expression of the membrane-cytoskeletal linker Ezrin in salivary gland adenoid cystic carcinoma. (21550270)
2011
25
Integrated, genome-wide screening for hypomethylated oncogenes in salivary gland adenoid cystic carcinoma. (21551254)
2011
26
Metastatic pleural effusion: a rare presentation of salivary gland adenoid cystic carcinoma. (21545072)
2011
27
Evolution pattern of the Runx3 gene 5'-CpG island methylation in human salivary gland adenoid cystic carcinoma]. (21223798)
2010
28
RUNX3 expression and its methylation of 5'-CpG island in salivary gland adenoid cystic carcinoma cell lines ACC-2, ACC-3 and ACC-M]. (21223819)
2010
29
RNAi knockdown of C-erbB2 expression inhibits salivary gland adenoid cystic carcinoma SACC-83 cell growth in vitro. (23554633)
2010
30
Sulforaphane induces G2-M arrest and apoptosis in high metastasis cell line of salivary gland adenoid cystic carcinoma. (19589718)
2009
31
Effects of Ezrin gene on the proliferation and invasion activity of human salivary gland adenoid cystic carcinoma]. (19575999)
2009
32
NF-kappaB promotes iNOS and VEGF expression in salivary gland adenoid cystic carcinoma cells and enhances endothelial cell motility in vitro. (19317804)
2009
33
Synergistic inhibitory effect of sulforaphane and 5-fluorouracil in high and low metastasis cell lines of salivary gland adenoid cystic carcinoma. (18844240)
2009
34
Response to oxaliplatin with cetuximab in minor salivary gland adenoid cystic carcinoma. (19688981)
2009
35
Choroidal metastasis from submandibular salivary gland adenoid cystic carcinoma. (18254353)
2008
36
Tamoxifen for salivary gland adenoid cystic carcinoma: report of two cases. (18347813)
2008
37
Coordinated expression of activated mitogen-activated protein kinases in salivary gland adenoid cystic carcinoma. (18657296)
2008
38
High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. (18326020)
2008
39
Fine-needle aspiration biopsy as an auxiliary diagnostic tool on intraoral minor salivary gland adenoid cystic carcinoma. (18644520)
2008
40
DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. (17545515)
2007
41
In vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. (17543095)
2007
42
SIKVAV, a laminin alpha1-derived peptide, interacts with integrins and increases protease activity of a human salivary gland adenoid cystic carcinoma cell line through the ERK 1/2 signaling pathway. (17591960)
2007
43
Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. (17520682)
2007
44
Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma. (17113340)
2007
45
Laminin-1 and SIKVAV a laminin-1-derived peptide, regulate the morphology and protease activity of a human salivary gland adenoid cystic carcinoma cell line. (15006619)
2004
46
Frequent downregulation of 14-3-3 sigma protein and hypermethylation of 14-3-3 sigma gene in salivary gland adenoid cystic carcinoma. (15292943)
2004
47
Prognostic value of apoptosis and apoptosis-associated proteins in salivary gland adenoid cystic carcinoma. (15028021)
2004
48
C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. (12118104)
2002
49
Apoptosis-induced and -suppressed cells in salivary gland adenoid cystic carcinoma: correlation with histological growth patterns. (10522207)
1999
50
Estrogen and progesterone receptors in salivary gland adenoid cystic carcinoma. (8521108)
1995

Variations for Salivary Gland Adenoid Cystic Carcinoma

About this section

Cosmic variations for Salivary Gland Adenoid Cystic Carcinoma:

8 (show top 50)    (show all 297)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM1659125BIRC6salivary gland,NS,carcinoma,adenoid cystic carcinomac.9339T>Cp.T3113T0
2COSM1659102LIG1salivary gland,NS,carcinoma,adenoid cystic carcinomac.2382C>Tp.C794C0
3COSM498HRASskin,face,carcinoma,NSc.182A>Tp.Q61L0
4COSM34221TIE1salivary gland,NS,carcinoma,adenoid cystic carcinomac.2050G>Cp.A684P0
5COSM28055ALKsalivary gland,NS,carcinoma,adenoid cystic carcinomac.3522C>Ap.F1174L0
6COSM1659034POT1salivary gland,NS,carcinoma,adenoid cystic carcinomac.725A>Gp.Y242C0
7COSM143845AXIN1salivary gland,NS,carcinoma,adenoid cystic carcinomac.2524G>Ap.E842K0
8COSM34219BRCA2salivary gland,NS,carcinoma,adenoid cystic carcinomac.559G>Ap.E187K0
9COSM1659055KNTC1salivary gland,NS,carcinoma,adenoid cystic carcinomac.3149C>Gp.S1050*0
10COSM1659002ANKS4Bsalivary gland,NS,carcinoma,adenoid cystic carcinomac.313G>Tp.A105S0
11COSM585NRASskin,face,carcinoma,NSc.183A>Tp.Q61H0
12COSM44241TP53skin,face,carcinoma,NSc.592G>Tp.E198*0
13COSM499HRASsalivary gland,NS,carcinoma,adenocarcinomac.182A>Gp.Q61R0
14COSM564NRASskin,face,carcinoma,NSc.35G>Ap.G12D0
15COSM17467PTCH1skin,face,carcinoma,NSc.1726C>Tp.Q576*0
16COSM17522PTCH1skin,face,carcinoma,NSc.3586C>Tp.P1196S0
17COSM51381KITsalivary gland,face,carcinoma,adenoid cystic carcinomac.2386A>Gp.R796G0
18COSM29033PTCH1skin,face,carcinoma,NSc.2038G>Tp.E680*0
19COSM17483PTCH1skin,neck,carcinoma,NSc.1729-1G>Tp.?0
20COSM1658900NAV2salivary gland,NS,carcinoma,adenoid cystic carcinomac.4812C>Gp.D1604E0
21COSM17519PTCH1skin,face,carcinoma,NSc.463C>Tp.P155S0
22COSM1658854CHN2salivary gland,NS,carcinoma,adenoid cystic carcinomac.523A>Cp.N175H0
23COSM33969KITsalivary gland,NS,carcinoma,adenoid cystic carcinomac.1771T>Cp.F591L0
24COSM14464PTCH1skin,face,carcinoma,NSc.1804C>Tp.R602*0
25COSM776PIK3CAsalivary gland,NS,carcinoma,adenoid cystic carcinomac.3140A>Tp.H1047L0
26COSM44435TP53skin,face,carcinoma,NSc.96+1G>Ap.?0
27COSM1658965DYRK4salivary gland,mouth roof,carcinoma,adenoid cystic carcinomac.1733G>Ap.R578H0
28COSM29048PTCH1skin,face,carcinoma,NSc.1347+1G>Ap.?0
29COSM88749CREBBPsalivary gland,NS,carcinoma,adenoid cystic carcinomac.4336C>Tp.R1446C0
30COSM1060622ACSL6salivary gland,NS,carcinoma,adenoid cystic carcinomac.911C>Tp.T304M0
31COSM1658867NOTCH1salivary gland,NS,carcinoma,adenoid cystic carcinomac.5105T>Cp.F1702S0
32COSM10656TP53skin,face,carcinoma,NSc.742C>Tp.R248W0
33COSM1659071WASF2salivary gland,mouth roof,carcinoma,adenoid cystic carcinomac.15G>Tp.T5T0
34COSM1659005CAMK1Gsalivary gland,NS,carcinoma,adenoid cystic carcinomac.323G>Tp.R108L0
35COSM43582TP53skin,face,carcinoma,NSc.454C>Tp.P152S0
36COSM1658915ALOX15salivary gland,NS,carcinoma,adenoid cystic carcinomac.1819G>Ap.G607S0
37COSM1658995HCRTR2salivary gland,NS,carcinoma,adenoid cystic carcinomac.1166G>Tp.R389L0
38COSM17584PTCH1skin,face,carcinoma,NSc.2105C>Tp.P702L0
39COSM483HRASskin,face,carcinoma,NSc.35G>Tp.G12V0
40COSM17511PTCH1skin,face,carcinoma,NSc.3583A>Tp.T1195S0
41COSM17598PTCH1skin,face,carcinoma,NSc.550C>Tp.Q184*0
42COSM29147PTCH1skin,face,carcinoma,NSc.1356T>Gp.Y452*0
43COSM1658780KDM6Asalivary gland,mouth roof,carcinoma,adenoid cystic carcinomac.2833-1G>Ap.?0
44COSM13146SMOskin,face,carcinoma,NSc.1604G>Tp.W535L0
45COSM17498PTCH1skin,face,carcinoma,NSc.2033C>Tp.T678I0
46COSM1659047HECTD4salivary gland,mouth roof,carcinoma,adenoid cystic carcinomac.6707G>Ap.S2236N0
47COSM1659060CHD2salivary gland,NS,carcinoma,adenoid cystic carcinomac.4919G>Ap.W1640*0
48COSM1658966SCN10Asalivary gland,NS,carcinoma,adenoid cystic carcinomac.599C>Tp.A200V0
49COSM1658882ZNF507salivary gland,NS,carcinoma,adenoid cystic carcinomac.34C>Ap.P12T0
50COSM1024904SEC23Bsalivary gland,NS,carcinoma,adenoid cystic carcinomac.5C>Tp.A2V0

Copy number variations for Salivary Gland Adenoid Cystic Carcinoma from CNVD:

6 (show top 50)    (show all 209)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1138051161300000DeletionAdenoid cystic carcinoma
23180913120000032688000LossBAI2Adenoid cystic carcinoma
33181013120000032688000LossEIF3S2Adenoid cystic carcinoma
43181113120000032688000LossFABP3Adenoid cystic carcinoma
53181213120000032688000LossHDAC1Adenoid cystic carcinoma
63181313120000032688000LossIQCCAdenoid cystic carcinoma
73181413120000032688000LossKHDRBS1Adenoid cystic carcinoma
83181513120000032688000LossLCKAdenoid cystic carcinoma
93181613120000032688000LossMARCKSL1Adenoid cystic carcinoma
103181713120000032688000LossPTP4A2Adenoid cystic carcinoma
113181813120000032688000LossPUM1Adenoid cystic carcinoma
123181913120000032688000LossRBBP4Adenoid cystic carcinoma
133182013120000032688000LossSERINC2Adenoid cystic carcinoma
143182113120000032688000LossTXLNAAdenoid cystic carcinoma
153392815061800052179000LossCDKN2CAdenoid cystic carcinoma
163392915061800052179000LossEPS15Adenoid cystic carcinoma
173393015061800052179000LossFAF1Adenoid cystic carcinoma
183393115061800052179000LossNRD1Adenoid cystic carcinoma
193393215061800052179000LossRAB3BAdenoid cystic carcinoma
203393315061800052179000LossRNF11Adenoid cystic carcinoma
215014311114500000121200000DeletionAdenoid cystic carcinoma
225014611114500000121200000GainSalivary gland adenoid cystic carcinoma
2358545116840000070400000DeletionAdenoid cystic carcinoma
2458546116840000070400000GainSalivary gland adenoid cystic carcinoma
256197012103800000109000000LOHAdenoid cystic carcinoma
266428312125900000133851895LOHAdenoid cystic carcinoma
27670681235800000133851895LossAdenoid cystic carcinoma
2867236123820000058100000DeletionAdenoid cystic carcinoma
2967639124374300050676000LossACVR1BAdenoid cystic carcinoma
3067640124374300050676000LossACVRL1Adenoid cystic carcinoma
3167641124374300050676000LossADCY6Adenoid cystic carcinoma
3267642124374300050676000LossAMIGO2Adenoid cystic carcinoma
3367643124374300050676000LossANP32DAdenoid cystic carcinoma
3467644124374300050676000LossARF3Adenoid cystic carcinoma
3567645124374300050676000LossATF1Adenoid cystic carcinoma
3667646124374300050676000LossCCNT1Adenoid cystic carcinoma
3767647124374300050676000LossCOL2A1Adenoid cystic carcinoma
3867648124374300050676000LossDDX23Adenoid cystic carcinoma
3967649124374300050676000LossFAIM2Adenoid cystic carcinoma
4067650124374300050676000LossHDAC7AAdenoid cystic carcinoma
4167651124374300050676000LossLALBAAdenoid cystic carcinoma
4267652124374300050676000LossLETMD1Adenoid cystic carcinoma
4367653124374300050676000LossLIMA1Adenoid cystic carcinoma
4467654124374300050676000LossMLL2Adenoid cystic carcinoma
4567655124374300050676000LossPFKMAdenoid cystic carcinoma
4667656124374300050676000LossPLEKHA9Adenoid cystic carcinoma
4767657124374300050676000LossPRKAG1Adenoid cystic carcinoma
4867658124374300050676000LossRACGAP1Adenoid cystic carcinoma
4967659124374300050676000LossRAPGEF3Adenoid cystic carcinoma
5067660124374300050676000LossRHEBL1Adenoid cystic carcinoma

Expression for genes affiliated with Salivary Gland Adenoid Cystic Carcinoma

About this section
Search GEO for disease gene expression data for Salivary Gland Adenoid Cystic Carcinoma.

Pathways for genes affiliated with Salivary Gland Adenoid Cystic Carcinoma

About this section

GO Terms for genes affiliated with Salivary Gland Adenoid Cystic Carcinoma

About this section

Cellular components related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cortical cytoskeletonGO:00308639.4CTTN, NOS2

Biological processes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1response to UV-AGO:007014110.0CCND1, EGFR
2dopaminergic neuron differentiationGO:007154210.0EN1, VEGFA
3mammary gland alveolus developmentGO:00607499.9CCND1, VEGFA
4cellular response to dexamethasone stimulusGO:00715499.6AQP1, EGFR
5positive regulation of protein phosphorylationGO:00019349.3CCND1, EGFR, VEGFA
6positive regulation of MAP kinase activityGO:00434069.2EGFR, KIT, VEGFA
7positive regulation of cell migrationGO:00303358.9EGFR, KIT, VEGFA
8Wnt signaling pathwayGO:00160558.9CCND1, CYLD, WIF1
9positive regulation of cell proliferationGO:00082848.6CCND1, EGFR, KIT, VEGFA

Molecular functions related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor signaling protein tyrosine kinase activityGO:000471610.3EGFR, KIT
2proline-rich region bindingGO:007006410.2CCND1, CYLD
3transmembrane receptor protein tyrosine kinase activityGO:000471410.1EGFR, KIT
4protein bindingGO:00055155.2AQP1, CCND1, CTTN, CYLD, EGFR, EN1

Sources for Salivary Gland Adenoid Cystic Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet